- nsh is planning to culture bacteriophages to extract endolysins as a DIY treatment for chronic eczema, noting that the basic methods have been canonical since 1956 and expressing frustration that this option was never previously suggested.  
- kanzure offers to fund nsh’s bacteriophage work and questions whether commercial endolysins can simply be purchased instead.  
- kanzure circulated a 15-page concept note (“beacon.pdf”) describing the use of benign, engineered brain parasites that migrate to specific regions, form cysts to mechanically displace neural tissue, and secrete nootropic compounds directly into the brain.  
- Lemminkainen highlighted two recent papers: ACS Nano on 90 % efficient Cas9-ribonucleoprotein delivery via gold nanoparticles for direct cytosolic gene editing, and a Nature Reviews Cancer article on recurrent architectures of tumor initiation, progression and drug sensitivity.  
- Lemminkainen also pointed to Nimbus Therapeutics’ structure-based drug-design platform as an interesting approach.  
- kanzure live-linked the IndieBio Demo Day roster, summarizing seven startups: BioInspira (biological chemical-leak sensors), AnimalBiome (microbiome testing and fecal transplants for pets), Catalog DNA (DNA-based data storage), GEA Enzymes (enzyme optimization), NeuroQore (rTMS devices), Ravata Solutions (rapid transgenic-animal platform), and Scaled Biolabs (microfluidics cell-culture platform).  
- A New York Times article was shared on the Trump administration’s opportunity to accelerate FDA drug approvals by leaving the commissioner post vacant.  
- Additional technical links included a robust-adaptive-control textbook (relevant to self-replicating factories), a paper on taste/smell GPCRs in lung tissue as a novel chemosensory system, and a Science Translational Medicine report showing that tau reduction prevents neuronal loss and reverses pathological tau deposition in mice.